Leroy Herbert, MD
Nephrology · New York, NYNPI 1285635953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 43.1% of the total. Reporting peaked in 2019 at $173 and has fallen 83.2% since, to $29 in 2025. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
Across 20 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$243
- Mallinckrodt Enterprises LLC$75
- Outset Medical Inc$56
- Calliditas Therapeutics US Inc.$48
- AstraZeneca$47
- Ardelyx, Inc.$29
- plus $66 from 3 others
Across 9 payments — averaging $86,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$774K
What the payments were for
- Food & beverage$563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $243 |
| Mallinckrodt Enterprises LLC | 3 | $75 |
| Outset Medical Inc | 1 | $56 |
| Calliditas Therapeutics US Inc. | 2 | $48 |
| AstraZeneca | 2 | $47 |
| Ardelyx, Inc. | 1 | $29 |
| GSK | 1 | $27 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
How this compares
$563 in reported general payments places this provider in the 45th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 12 | $25,100 |
| Sevelamer Carbonate | 49 | $10,529 |
| Calcium Acetate | 12 | $557 |
| Nifedipine ErNifedipine | 30 | $495 |
| Metolazone | 13 | $432 |
| Allopurinol | 20 | $193 |
| Carvedilol | 11 | $126 |
| Amlodipine Besylate | 17 | $116 |
| Simvastatin | 14 | $88 |
| Zolpidem Tartrate | 19 | $54 |
| Folic Acid | 19 | $51 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.